Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience
Background & Aims. Current polychemotherapeutic protocols based on differentiated and risk-adopted approaches permitted to consider non-Hodgkin’s lymphomas (NHL) potentially curable diseases although they had been considered fatal previously. The aim of this study is to summarize and analyze out...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2016-10-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/en/non-hodgkin-s-lymphomas-in-children-25-year-clinical-experience-2/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849415254417604608 |
|---|---|
| author | TT Valiev AV Popa AS Levashov ES Belyaeva NS Kulichkina BV Kurdyukov RS Ravshanova GL Mentkevich |
| author_facet | TT Valiev AV Popa AS Levashov ES Belyaeva NS Kulichkina BV Kurdyukov RS Ravshanova GL Mentkevich |
| author_sort | TT Valiev |
| collection | DOAJ |
| description | Background & Aims. Current polychemotherapeutic protocols based on differentiated and risk-adopted approaches permitted to consider non-Hodgkin’s lymphomas (NHL) potentially curable diseases although they had been considered fatal previously. The aim of this study is to summarize and analyze outcomes of NHL therapy over a 25-year period.
Methods. 246 patients were enrolled in the study. They were treated in the department of chemotherapy of hemoblastoses in the Scientific Research Institute of Pediatric Oncology and Hematology under the NN Blokhin Russian Cancer Research Center over the period of 25 years: from April 1, 1991, till June 1, 2016. B-NHL-BFM 90/95 protocols and a modified B-NHL-BFM 95 protocol (with rituximab) were used for B-cell NHLs (n = 130). Patients with lymphocytic leukemia (n = 75) were treated using ALL-mBFM 90/95 and ALL IC-BFM 2002 protocols. 21 patients with anaplastic large cell lymphomas (ALCL) received treatment according to the B-NHL-BFM 90/95 protocol, and 20 patients received the НИИ ДОГ-АККЛ-2007 protocol.
Results. Taking into account clinical and immunological characteristics of ALCL, the authors invented an original НИИ ДОГ-АККЛ-2007 protocol. Special attention was paid to potential modification of standard treatment regimens for B-cell NHL by adding rituximab. The article demonstrates the evolution in prescription of rituximab for B-cell NHL and possibilities for reduction of the total number of polychemotherapy cycles for late-stage tumors without deterioration of treatment outcomes.
Conclusion. The obtained results permit to conclude that introduction of achievements of oncoimmunology, molecular biology, and cytogenetics will become the basis for further modification of existing treatment options for NHL. |
| format | Article |
| id | doaj-art-56e0800a86fd4c6cbfc1aadcddc33f7b |
| institution | Kabale University |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2016-10-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-56e0800a86fd4c6cbfc1aadcddc33f7b2025-08-20T03:33:35ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392016-10-019442043710.21320/2500-2139-2016-9-4-420-437Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical ExperienceTT Valiev0AV Popa1AS Levashov2ES Belyaeva3NS Kulichkina4BV Kurdyukov5RS Ravshanova6GL Mentkevich7Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Background & Aims. Current polychemotherapeutic protocols based on differentiated and risk-adopted approaches permitted to consider non-Hodgkin’s lymphomas (NHL) potentially curable diseases although they had been considered fatal previously. The aim of this study is to summarize and analyze outcomes of NHL therapy over a 25-year period. Methods. 246 patients were enrolled in the study. They were treated in the department of chemotherapy of hemoblastoses in the Scientific Research Institute of Pediatric Oncology and Hematology under the NN Blokhin Russian Cancer Research Center over the period of 25 years: from April 1, 1991, till June 1, 2016. B-NHL-BFM 90/95 protocols and a modified B-NHL-BFM 95 protocol (with rituximab) were used for B-cell NHLs (n = 130). Patients with lymphocytic leukemia (n = 75) were treated using ALL-mBFM 90/95 and ALL IC-BFM 2002 protocols. 21 patients with anaplastic large cell lymphomas (ALCL) received treatment according to the B-NHL-BFM 90/95 protocol, and 20 patients received the НИИ ДОГ-АККЛ-2007 protocol. Results. Taking into account clinical and immunological characteristics of ALCL, the authors invented an original НИИ ДОГ-АККЛ-2007 protocol. Special attention was paid to potential modification of standard treatment regimens for B-cell NHL by adding rituximab. The article demonstrates the evolution in prescription of rituximab for B-cell NHL and possibilities for reduction of the total number of polychemotherapy cycles for late-stage tumors without deterioration of treatment outcomes. Conclusion. The obtained results permit to conclude that introduction of achievements of oncoimmunology, molecular biology, and cytogenetics will become the basis for further modification of existing treatment options for NHL.http://bloodjournal.ru/en/non-hodgkin-s-lymphomas-in-children-25-year-clinical-experience-2/Burkitt lymphomadiffuse large B-cell lymphomaanaplastic large-cell lymphomaprimary mediastinal (thymic) large B-cell lymphomaT- and B-cell lymphoblastic lymphomastreatmentchildren |
| spellingShingle | TT Valiev AV Popa AS Levashov ES Belyaeva NS Kulichkina BV Kurdyukov RS Ravshanova GL Mentkevich Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience Клиническая онкогематология Burkitt lymphoma diffuse large B-cell lymphoma anaplastic large-cell lymphoma primary mediastinal (thymic) large B-cell lymphoma T- and B-cell lymphoblastic lymphomas treatment children |
| title | Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience |
| title_full | Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience |
| title_fullStr | Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience |
| title_full_unstemmed | Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience |
| title_short | Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience |
| title_sort | non hodgkin s lymphomas in children 25 year clinical experience |
| topic | Burkitt lymphoma diffuse large B-cell lymphoma anaplastic large-cell lymphoma primary mediastinal (thymic) large B-cell lymphoma T- and B-cell lymphoblastic lymphomas treatment children |
| url | http://bloodjournal.ru/en/non-hodgkin-s-lymphomas-in-children-25-year-clinical-experience-2/ |
| work_keys_str_mv | AT ttvaliev nonhodgkinslymphomasinchildren25yearclinicalexperience AT avpopa nonhodgkinslymphomasinchildren25yearclinicalexperience AT aslevashov nonhodgkinslymphomasinchildren25yearclinicalexperience AT esbelyaeva nonhodgkinslymphomasinchildren25yearclinicalexperience AT nskulichkina nonhodgkinslymphomasinchildren25yearclinicalexperience AT bvkurdyukov nonhodgkinslymphomasinchildren25yearclinicalexperience AT rsravshanova nonhodgkinslymphomasinchildren25yearclinicalexperience AT glmentkevich nonhodgkinslymphomasinchildren25yearclinicalexperience |